MG treatment was broadly similar across the three Nordic countries, while also reflecting nation-specific therapeutic guidelines. Many pwMG required multiple therapies, underscoring risks of long-term immunosuppression and highlighting the need for vigilant management and future research of safer strategies.
Atula et al. (Sun,) studied this question.